Literature DB >> 12614635

Neuroendocrine aspects of hypercortisolism in major depression.

Karen J Parker1, Alan F Schatzberg, David M Lyons.   

Abstract

A consistent finding in biological psychiatry is that hypothalamic-pituitary-adrenal (HPA) axis physiology is altered in humans with major depression. These findings include hypersecretion of cortisol at baseline and on the dexamethasone suppression test. In this review, we present a process-oriented model for HPA axis regulation in major depression. Specifically, we suggest that acute depressions are characterized by hypersecretion of hypothalamic corticotropin-releasing factor, pituitary adrenocorticotropic hormone (ACTH), and adrenal cortisol. In chronic depressions, however, enhanced adrenal responsiveness to ACTH and glucocorticoid negative feedback work in complementary fashion so that cortisol levels remain elevated while ACTH levels are reduced. In considering the evidence for hypercortisolism in humans, studies of nonhuman primates are presented and their utility and limitations as comparative models of human depression are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614635     DOI: 10.1016/s0018-506x(02)00016-8

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  118 in total

1.  Modulation of sphingosine 1-phosphate and tyrosine hydroxylase in the stress-induced anxiety.

Authors:  Soyong Jang; Donghyun Kim; Yeonju Lee; Sohyeon Moon; Seikwan Oh
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

Review 2.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 3.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 4.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

5.  A neural pathway controlling motivation to exert effort.

Authors:  Christophe D Proulx; Sage Aronson; Djordje Milivojevic; Cris Molina; Alan Loi; Bradley Monk; Steven J Shabel; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-11       Impact factor: 11.205

Review 6.  Biological risk factors for late life depression.

Authors:  Henning Tiemeier
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

7.  Prenatal alcohol exposure increases vulnerability to stress and anxiety-like disorders in adulthood.

Authors:  Kim G C Hellemans; Pamela Verma; Esther Yoon; Wayne Yu; Joanne Weinberg
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 8.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  What sleeping babies hear: a functional MRI study of interparental conflict and infants' emotion processing.

Authors:  Alice M Graham; Philip A Fisher; Jennifer H Pfeifer
Journal:  Psychol Sci       Date:  2013-03-28

Review 10.  Future directions in vulnerability to depression among youth: integrating risk factors and processes across multiple levels of analysis.

Authors:  Benjamin L Hankin
Journal:  J Clin Child Adolesc Psychol       Date:  2012-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.